Key Highlights

  • NeuroScientific Biopharmaceuticals (ASX:NSB) is trading at AUD$0.064 during the 13 August 2026 session as investors assess the company's advancing regulatory program.
  • The US FDA has scheduled a Pre-Investigational New Drug meeting for 31 August 2026 concerning NSB's planned Phase 2 trial in refractory Crohn's disease.
  • The company is preparing an IND application targeted for submission by late 2026 for a Phase 2 trial involving patients in the United States and Australia.
  • StemSmart is the company's patented mesenchymal stem cell technology platform, with refractory and fistulising Crohn's disease forming the current clinical development focus.

Share Performance Comes Under Focus as Regulatory Timeline Advances

NeuroScientific Biopharmaceuticals (ASX:NSB) is attracting market attention during trading on 13 August 2026 as the biotechnology company moves toward a scheduled regulatory discussion with the US Food and Drug Administration. NSB shares are trading at AUD$0.064 during the session, while the company's latest announcement places regulatory preparation for its planned Phase 2 refractory Crohn's disease trial at the centre of its current development agenda.

The FDA has confirmed 31 August as the date for a Pre-IND meeting with NeuroScientific. The meeting concerns the proposed US clinical program for StemSmart, the company's stem cell technology platform targeting severe immune-mediated inflammatory diseases.

FDA Pre-IND Meeting Sets Near-Term Regulatory Milestone

A Pre-IND meeting provides an opportunity for a biotechnology company to discuss its proposed clinical development and regulatory pathway with the FDA before submitting an Investigational New Drug application. For NeuroScientific, the scheduled meeting is intended to address the proposed design of its Phase 2 trial in refractory Crohn's disease.

The company is targeting an IND submission by late 2026. Its planned Phase 2 study is intended to include patients in both the United States and Australia, placing the upcoming FDA interaction within a broader clinical development program rather than as an isolated regulatory event.

The outcome of the meeting is expected to provide feedback relevant to the clinical design and development requirements for the planned trial. NeuroScientific has indicated that the discussion will support ongoing preparation for the Phase 2 program.

StemSmart Remains Central to the Clinical Strategy

StemSmart is derived from adult human donor bone marrow-sourced mesenchymal stem cells. NeuroScientific says its patented Manufacturing process has been developed to improve therapeutic activity and clinical response while modulating pathological immune responses associated with chronic inflammatory conditions.

The company is initially targeting refractory Crohn's disease, a treatment-resistant form of the condition. Its development strategy also encompasses fistulising Crohn's disease, where the company has been generating clinical information through its Special Access Program.

In May, NeuroScientific reported that five patients had received StemSmart under the program, with four achieving its defined clinical-response measure and no serious adverse events reported. The company subsequently initiated preparations for a Phase 2 trial in fistulising Crohn's disease in Australia, alongside the broader refractory Crohn's disease program.

Clinical Development Creates a Broader Regulatory Pathway

The planned Phase 2 program represents a transition from earlier clinical experience toward a more structured trial intended to evaluate StemSmart in a defined patient population. The regulatory engagement with the FDA is therefore relevant to the design and execution of the proposed US component.

NeuroScientific's current program follows a series of developments around StemSmart, including the Acquisition of the underlying technology and subsequent clinical work in Crohn's disease. The company has described the technology as a platform aimed at immune-mediated inflammatory disorders where existing treatments may provide inadequate or limited-duration responses.

Market Focus Shifts Toward Execution

For the NSB share performance story during the 13 August session, the scheduled FDA meeting provides a clearly defined near-term corporate milestone. The company's next stages involve regulatory interaction, continued preparation of the Phase 2 clinical program and the intended IND submission later in the year.

The distinction between regulatory progress and clinical outcomes remains important. A Pre-IND meeting does not establish the efficacy or safety of a treatment in a future Phase 2 population; rather, it forms part of the regulatory process preceding an IND submission and clinical trial.

Conclusion

NeuroScientific Biopharmaceuticals (ASX:NSB) is entering a regulatory-focused period as it prepares for the 31 August Pre-IND meeting with the US FDA. The company's development strategy centres on StemSmart and its application in refractory Crohn's disease, supported by preparations for Phase 2 trials across the US and Australia. With an IND submission targeted for late 2026, the company's near-term trajectory is increasingly defined by regulatory execution and clinical-trial preparation. The share performance during the 13 August Trading session therefore sits against a backdrop of a biotechnology program moving toward its next formal development stage.